Medical News

RSS

Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

Circadian Technologies Limited announces that its 100% owned subsidiary, Vegenics Pty Ltd, has received approval for its investigational new drug application from the U.S. Food and Drug Administration to initiate clinical trials of VGX-100.

31 Oct 2011

Political cartoon: 'Great Pumpkin'

Kaiser Health News provides a fresh perspective on health policy developments with "Great Pumpkin" by Lisa Benson.

31 Oct 2011

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

Haemonetics second quarter net revenues increase 8% to $179.4 million

Haemonetics Corporation today reported second quarter 2012 GAAP net revenues of $179.4 million, up 8%, net income of $13.9 million, down 35%, and earnings per share of $0.54, down 36%. Excluding transformation costs and contingent consideration income, adjusted second quarter net income was $18.7 million, down 7%, and adjusted earnings per share was $0.72, down 9%. Excluding currency impacts, net revenue was up 6% in the quarter.

31 Oct 2011

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

Infinity Pharmaceuticals, Inc. today announced that it has initiated two Phase 1 clinical trials of IPI-145, a potent, orally available inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma. These two enzymes are implicated in hematologic cancers as well as a broad range of inflammatory conditions, which are the areas of focus within Infinity's PI3K clinical development program.

31 Oct 2011

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced favorable response and safety indications from a group of patients with advanced solid tumors (principally soft tissue sarcomas) in the Company's ongoing Phase 1b/2 clinical trial with INNO-206, its tumor-targeting conjugate of the commonly used chemotherapeutic agent doxorubicin.

31 Oct 2011

First Edition: October 31, 2011

In today's headlines, news reports about a key medical group's take on accountable care organizations and how a "merger wave" is hitting the health care sector.

31 Oct 2011

Avanir seeks EMA marketing authorization for NUEDEXTA to treat pseudobulbar affect

Avanir Pharmaceuticals, Inc. announced today that it has submitted an application to the European Medicines Agency seeking marketing authorization for NUEDEXTA (dextromethorphan HBr and quinidine sulfate) for the treatment of pseudobulbar affect.

31 Oct 2011

AgonOx, MedImmune partner to advance OX40 agonist programs for cancer treatment

AgonOx today announced that it has entered into an exclusive global partnership with MedImmune, the global biologics arm of AstraZeneca, to develop agonists using its OX40 platform. MedImmune will lead further preclinical and clinical studies of this tumor-specific T-cell immunity stimulator for the potential treatment of cancer.

31 Oct 2011

Centracare chooses Merge's iConnect for image interoperability, informatics strategy

Merge Healthcare, a leading provider of enterprise imaging and interoperability solutions, today announced that Centracare Health System's St. Cloud Hospital, the largest healthcare provider in the St. Cloud, MN region, has selected Merge's iConnect VNA (vendor neutral archive) and iConnect Share for their image interoperability and informatics strategy.

31 Oct 2011

YM BioSciences announces results of nimotuzumab Phase II study on DIPG

YM BioSciences Inc. today announced that preliminary results of a Phase II study evaluating the safety and efficacy of nimotuzumab in pediatric patients with recurrent diffuse intrinsic pontine glioma (DIPG) were reported at the 43rd Congress of the International Society of Paediatric Oncology (SIOP) conference being held in Auckland, New Zealand.

31 Oct 2011

Gen-Probe receives FDA approval for APTIMA HPV assay

Gen-Probe Incorporated announced today that the US Food and Drug Administration (FDA) has approved its APTIMA HPV assay, an amplified nucleic acid test that detects high-risk strains of human papillomavirus (HPV) that are associated with cervical cancer and precancerous lesions.

31 Oct 2011

WageWorks launches EZ Receipts to manage healthcare, dependent care spending accounts

WageWorks, Inc., a leading on-demand provider of tax-advantaged programs for consumer-directed health, commuter and other employee spending account benefits, is pleased to announce the launch of its new EZ Receipts mobile application for use by WageWorks' participants on their smartphones and other mobile devices.

31 Oct 2011

COPCP chooses eClinicalWorks comprehensive EHR solution

eClinicalWorks, a market leader in ambulatory clinical systems, today announced that Central Ohio Primary Care Physicians (COPCP), the second largest privately-owned primary care group in the United States, has chosen eClinicalWorks comprehensive electronic health records (EHR) solution for its 230 physicians across 44 practices.

31 Oct 2011

Auxilium reports net revenues of $66.7 million for third quarter 2011

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced financial results and operational highlights for the quarter ended September 30, 2011.

31 Oct 2011

New antibiotic regimes may increase infections after specific surgical procedures

The introduction of new antibiotic regimes to tackle hospital-acquired infections, such as C. difficile, must take into account the possibility of increased infections following specific surgical procedures.

31 Oct 2011

PPRT publishes study that evaluates pharmacist provision of clozapine

According to a study which evaluated alternative models for the delivery of clozapine services, published by the Pharmacy Practice Research Trust (PPRT), there is scope to review the team configurations needed to deliver community services in a cost-effective manner and to provide opportunities for improving the services provided to patients.

31 Oct 2011

Toshiba’s Infinix DP-i cardiovascular X-ray system to be used in eight live cases

Enabling clinicians to seamlessly transition between cardiac and peripheral intervention during a single procedure, Infinix DP-i cardiovascular X-ray system from Toshiba America Medical Systems, Inc. will be used in eight live cases at Peripheral Angioplasty and All That Jazz conference, Oct. 31 - Nov. 2, 2011, New Orleans.

31 Oct 2011

GC-C agonists have potential to delay progression of colitis into colon cancer

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, today announced that poster P409 presented at the upcoming 2011 annual scientific meeting of the American College of Gastroenterology highlights the potential use of guanylate cyclase-C agonists to delay progression of colitis into colon cancer.

31 Oct 2011

Pacira's third quarter total revenues decrease to $4.0 million

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced financial results for the third quarter ended September 30, 2011 and provided an update on the U.S. Food and Drug Administration's (FDA) approval of EXPAREL and the commercial strategy to support the product launch.

31 Oct 2011

Medical News

Vegenics receives IND approval from FDA for VGX-100 Phase I study in late stage cancers

Political cartoon: 'Great Pumpkin'

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Haemonetics second quarter net revenues increase 8% to $179.4 million

Infinity commences two IPI-145 Phase 1 clinical trials for hematologic malignancies

Positive initial results from CytRx's INNO-206 Phase 1b/2 clinical trial for advanced solid tumors

First Edition: October 31, 2011

Avanir seeks EMA marketing authorization for NUEDEXTA to treat pseudobulbar affect

AgonOx, MedImmune partner to advance OX40 agonist programs for cancer treatment

Centracare chooses Merge's iConnect for image interoperability, informatics strategy

YM BioSciences announces results of nimotuzumab Phase II study on DIPG

Gen-Probe receives FDA approval for APTIMA HPV assay

WageWorks launches EZ Receipts to manage healthcare, dependent care spending accounts

COPCP chooses eClinicalWorks comprehensive EHR solution

Auxilium reports net revenues of $66.7 million for third quarter 2011

New antibiotic regimes may increase infections after specific surgical procedures

PPRT publishes study that evaluates pharmacist provision of clozapine

Toshiba’s Infinix DP-i cardiovascular X-ray system to be used in eight live cases

GC-C agonists have potential to delay progression of colitis into colon cancer

Pacira's third quarter total revenues decrease to $4.0 million

Advancing Menopause Care: Non-Hormonal Treatments for Vasomotor Symptoms

Building quality into drug development for safer, faster medicines

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

Latest News